| Identification | Back Directory | [Name]
Bersanlimab | [CAS]
1987854-08-9 | [Synonyms]
BI-505
Bersanlimab
Research Grade Bersanlimab
Research Grade Bersanlimab(DHC16001) |
| Hazard Information | Back Directory | [Uses]
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects[1]. | [in vivo]
Bersanlimab (BI-505; 20 mg/kg; i.p.; twice-weekly; for 21 days) significantly reduceds tumor growth and prolonges animal survival[1]. | Animal Model: | SCID mice injected with ARH-77 cells[1] | | Dosage: | 20 mg/kg | | Administration: | i.p.; twice-weekly; for 21 days | | Result: | Significantly reduced tumor growth and prolonged animal survival. |
| [References]
[1] Niina Veitonm?ki, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15. DOI:10.1016/j.ccr.2013.02.026 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|